Exeltis USA v. Glenmark: Contraceptive Patent Suit Dismissed With Prejudice
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Exeltis USA, Inc. v. Glenmark Pharmaceuticals |
| Numéro de dossier | 2:25-cv-17250 (D.N.J.) |
| Tribunal | Tribunal fédéral de première instance pour le district du New Jersey |
| Durée | Nov 2025 – Mar 2026 4 months |
| Résultat | Dismissed With Prejudice (No Damages Disclosed) |
| Brevets en cause | |
| Produits incriminés | Glenmark’s drospirenone formulations and pharmaceutical compositions |
Aperçu du dossier
Les parties
⚖️ Demandeur
U.S. commercial arm of a global specialty pharmaceutical company, marketing SLYND® (drospirenone) as a progestin-only oral contraceptive.
🛡️ Défendeur
Multinational generic and specialty drug manufacturer with significant U.S. market operations, seeking to introduce lower-cost alternatives.
Brevets en cause
This dispute involved an expansive portfolio of **18 U.S. patents** protecting the branded contraceptive SLYND® (drospirenone) and related pharmaceutical compositions and delivery methods. These patents collectively cover drospirenone-based pharmaceutical compositions, contraceptive kit configurations, and methods of administering synthetic progestogens, forming a dense defensive perimeter around the SLYND® product franchise.
- • US10849857B2, US11951213B2, US11123299B2, US10179140B2, US9603860B2
- • US11439598B2, US10603281B2, US12280151B2, US11291633B2, US10987364B1
- • US11413249B2, US11291632B2, US11491113B1, US11351122B1, US11452695B2
- • US11478487B1, US11504334B2, US12090231B2
Vous développez un produit pharmaceutique similaire ?
Check if your drospirenone formulation might infringe these or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The case was resolved by stipulated dismissal with prejudice as to all claims and defenses asserted by both parties. The dismissal order explicitly provides that no costs or attorneys’ fees were awarded to any party. No damages figure was publicly disclosed, and no injunctive relief was ordered as part of the public record.
Principales questions juridiques
The rapid resolution—without any substantive motions or claim construction proceedings concluding—suggests that **settlement leverage was asymmetric early**. With 18 patents asserted, Glenmark faced substantial litigation exposure and cost. The breadth of Exeltis’s portfolio likely accelerated settlement incentives. This case reinforces the strategic value of **layered patent portfolios** that protect a single drug franchise through overlapping claim scopes across composition, method-of-use, and formulation patents.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in contraceptive drug development. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View all 18 asserted patents in this technology space
- See which companies are most active in contraceptive patents
- Understand claim construction patterns for drospirenone
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Drospirenone-based pharmaceutical compositions
18 brevets revendiqués
Covering SLYND® franchise
Options de contournement
Feasible, but complex due to layered claims
✅ Points clés à retenir
Asserting a broad continuation patent portfolio (18 patents) creates compounding litigation exposure that accelerates defendant settlement behavior.
Rechercher la jurisprudence connexe →Stipulated dismissals with prejudice in pharma cases typically signal confidential licensing resolutions, not outright concessions.
Explorer les précédents →New Jersey remains a strategically preferred forum for branded pharmaceutical patent enforcement.
Explorer les analyses judiciaires →Foire aux questions
The case involved 18 U.S. patents covering drospirenone (SLYND®) compositions, synthetic progestogen formulations, contraceptive kits, and related methods of administration, including US10849857B2, US11951213B2, and US12280151B2, among others.
The parties filed a joint stipulation of dismissal with prejudice, with no costs or attorneys’ fees awarded. The public record contains no judicial rulings on infringement or validity, strongly suggesting a private settlement or licensing agreement.
It reinforces that broad, layered pharmaceutical patent portfolios—covering a single drug across multiple claim types—create significant litigation leverage, often producing early resolution before substantive merits proceedings.
Prêt à renforcer votre stratégie en matière de brevets pharmaceutiques ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER Case Lookup – Case No. 2:25-cv-17250
- USPTO Patent Full-Text Database for US10849857B2 and related patents
- Office américain des brevets et des marques — Ressources sur les brevets
- World Intellectual Property Organization — Pharmaceutical Patents
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.